# Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

> **NCT05286827** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 5 (actual)

## Conditions studied

- Pancreatic Acinar Cell Carcinoma

## Interventions

- **DRUG:** Olaparib
- **DIAGNOSTIC_TEST:** ECG
- **DIAGNOSTIC_TEST:** CT CAP
- **PROCEDURE:** Tumor Biopsy

## Key facts

- **NCT ID:** NCT05286827
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-12-14
- **Primary completion:** 2024-12-18
- **Final completion:** 2025-09-25
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The study was terminated due to low accrual and insufficient efficacy seen in first few participants treated.
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05286827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05286827, "Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05286827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*